ANALYSIS OF THE EFFECT THAT ANTIRESORTIVE DRUG HAS ON THE PERI-IMPLANT BONE TISSUE OF IMPLANTS ALREADY OSSEOINTEGRATED: HISTOLOGICAL AND IMMUNOHISTOCHEMICAL STUDY IN RATS

• Grant number: 23/03412-0
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: May 01, 2023
• End date: April 30, 2025
• Field of knowledge: Health Sciences - Dentistry - Oral and Maxillofacial Surgery
• Principal Investigator: Edilson Ervolino
• Grantee: Leandro Lemes da Costa
• Host Institution: Faculdade de Odontologia (FOA). Universidade Estadual Paulista (UNESP). Campus de Araçatuba. Araçatuba , SP, Brazil

Abstract

Medication-related osteonecrosis of the jaws (MRONJ) is an adverse effect triggered by the use of antiresorptive drugs. This is a condition that is difficult to treat and can result in serious sequelae, which make rehabilitation difficult or impossible and, consequently, compromise the quality of life of patients. In recent years, the number of cases of MRONJ related to dental implants (DI) already osseointegrated and functioning in the oral cavity has increased substantially. Understanding the pathophysiological mechanisms involved in this condition is necessary, especially in order to establish effective prevention and treatment strategies. The aim of this study will be to evaluate the histological characteristics and the main cytokines with pro-inflammatory activity in the bone tissue located around DI that are already osseointegrated in the maxilla of senescent female rats submitted to treatment with zoledronate after osseointegration has been achieved. In this study, 20 senescent female rats will be used. In the 0th week, the upper right first molar will be extracted and a titanium implant (length - 2.5 mm; diameter - 1.5 mm) will be installed in the dental extraction site previously occupied by its mesial root. In the 10th week, the rats will be divided into two groups: VEI, treated with vehicle, and ZOL, treated with vehicle added 100 ¼g/Kg of zoledronate. From the 10th to the 20th week, vehicle or zoledronate will be administered intraperitoneally every four days. In the 20th week the rats will be euthanized, an intraoral clinical evaluation will be carried out and the samples of the maxilla containing the implant will be dissected. Such samples will be submitted to conventional histological processing with hematoxylin-eosin staining and immunohistochemical processing to detect cytokines with pro-inflammatory activity, tumor necrosis factor alpha (TNF±), interleukin 1 beta (IL-1²) and interleukin 6 (IL-6). Histological analysis and immunolabeling density will be performed on the samples. The data obtained will be submitted to statistical analysis with a significance level of 5%.